This afternoon we watched Bristol-Myers Squibb Company drop -3.6% to a price of $67.73 per share. The large-cap Pharmaceutical company is now trading -15.47% below its average target price of $80.13. Analysts have set target prices ranging from $62.0 to $92.0 per share for Bristol-Myers Squibb Company, and have given the stock an average rating of buy.
Bristol-Myers Squibb Company's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.9%. The stock's short ratio is 2.27. At 0.07%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 78.6%. In conclusion, we believe there is mixed market sentiment regarding Bristol-Myers Squibb Company.
Institutions Invested in Bristol-Myers Squibb Company
|2022-12-31||Vanguard Group, Inc. (The)||10%||202,927,620||$13,745,302,464|
|2022-12-31||JP Morgan Chase & Company||5%||98,663,476||$6,682,970,607|
|2022-12-31||State Street Corporation||4%||92,750,001||$6,282,421,374|
|2022-12-31||Capital International Investors||3%||52,717,037||$3,570,788,533|
|2022-12-31||Bank of America Corporation||2%||40,126,060||$2,717,938,698|
|2022-12-31||Geode Capital Management, LLC||2%||38,724,114||$2,622,977,885|
|2022-12-31||Norges Bank Investment Management||1%||26,041,644||$1,763,930,772|